A s new or updated safety information emerges throughout a medicine's lifecycle, there are occasions when it is important to communicate this infor mation promptly to healthcare providers involved in prescribing or dispensing or in caring for patients who receive med icines. Such correspondence from the manufacturer or national regulatory agency -typically known as 'Dear Doctor' letters or direct healthcare professional communications -is vital to pharmaco vigilance by ensuring that prescribers are informed about new evidence of drug benefit and harm that has emerged postlicensing. 1 The correspondence com municates practical advice for the safe use of drugs with the aim of improving patient health outcomes.
How far these warnings actually influ ence prescribing behaviour is mixed. Studies of the impact of regulatory advi sory letters on medicines use have not been resoundingly positive. For instance, one review concluded that although some notices have a significant impact, others have a delayed or no impact. 2 This may be due to the nature and specificity of the warning: recommendations to monitor treatment more closely have little impact whereas recommendations to avoid use of a drug in particular patient subgroups often lead to reductions in use, espe cially if the risk communication states specific actions that prescribers should take. Another review could not reach firm conclusions because of the limited evi dence of any effect, though the authors found that healthcare professionals prefer to be informed by governmental or their own professional bodies, rather than by the pharmaceutical industry. 3 The 2007. It is based on robust analysis of pharmacovigilance data and evidence, describes the nature of drug safety problems and in the majority of cases outlines what actions should be taken to mitigate any identified risk. The GMC guidance on good practice in prescribing explicitly highlights that DSU provides information and advice to support the safer use of medicines and alerts prac titioners to safety information about medicines. 4 Furthermore, a competency framework for all prescribers has as one of the competencies: "Keeps up to date with emerging safety concerns related to prescribing." 5 An editorial in the Drug and Therapeutics Bulletin commented that DSU has established itself as one of the most influential sources of new infor mation about the safety of medicines for UKbased healthcare professionals, but also noted that on occasion, safety notices have not included any practical implementation advice. 6 Our small survey set out to under stand how different healthcare profes sionals in one CCG viewed the advice offered by the DSU newsletter.
Method
Across Cornwall, localitybased pre scribing meetings are held four times a year. These meetings, organised by NHS Kernow CCG Medicines Optimisation Team, are intended to have a focus on clinical prescribing and medicines optimi sation. A GP prescribing lead from each surgery is invited to attend these meet ings and disseminate the learning within their own practice. At each of the three locality meetings in March 2016, the GPs were asked to complete a questionnaire during the tea break having been advised that it was anonymous and would take only a few minutes to complete.
The survey was also delivered to a convenience sample of nurse nonmedi cal prescribers (NMPs) working in general practice who attended a prescribing and medicines optimisation educational event in May 2016, and to a convenience sample of community pharmacists who attended a local pharmaceutical committeeorganised educational event in July 2016.
The introduction to the survey sim ply noted that the DSU newsletter is produced each month and is intended to be essential reading for healthcare pro fessionals, bringing the very latest infor mation and advice to support the safer use of medicines. The survey consisted of mainly closed questions with predeter mined answers plus one question that allowed respondents to make freetext comments, and hence could be com pleted quickly (with the aim of achieving a high response rate). Questions were developed following a review of the lit erature and in discussion with the CCG prescribing lead.
The questions for the three profes sions were very similar apart from the question asking respondents for their views on how they perceive their col leagues' awareness of the DSU news letter. GPs and NMPs were asked about doctors (locums or partners) in the sur gery where they were based, and commu nity pharmacists were asked about their pharmacy colleagues (locums or regular staff) in their place of work.
Results
The three GP meetings were attended by a total of 44 GPs, with completed questionnaires returned from 38 (86%). All attendees (26) There were some differences between the professional groups in how they perceived being made aware of the DSU newsletter (see Table 1 ). A greater proportion of pharmacists claimed to be registered with the MHRA service, while a greater proportion of NMPs answered that they did not have a formal process to be made aware of the DSU newsletter. More than half (50-82%) of each pro fession recognised that they receive an additional communication from the CCG prescribing team highlighting DSU topics.
Regarding the usefulness of the DSU newsletter (see Table 2 ), similar pro portions of each profession (63-81%) responded that a few of the topics are of relevance and it is always clear what action should be taken.
When asked to name one or two examples where they perceived that pre scribing or monitoring of drug use had altered as a result of a DSU newsletter, 32 responses were received across all three health professional groups (see Table 3 ). Valproate, domperidone and metoclopramide were the most frequently named medicines. More pharmacists in particular named some medicines that had not appeared in a DSU newsletter.
A larger proportion (20%) of pharma cists than GPs or NMPs expressed con cern over perceptions that their colleagues lacked awareness of the DSU newsletter, though approximately half of the GPs and NMPs indicated that they do not know how aware their respective colleagues are of the DSU newsletter (see Table 4 ).
Fourteen (37%) GPs, 15 (58%) NMPS and 16 (80%) pharmacists wished there were other resources to which they could refer because they think that drug safety advice is an important aspect of use of medicines and they worry about knowl edge gaps. The remainder of respond ents indicated that they receive enough information about this topic.
Freetext comments were invited on the subject of drug safety and responses were received from nine GPs and two pharmacists. The two main themes from these 11 comments were about infor mation overload for the practitioner, and ensuring that the relevance and impor tance of the drug safety topic is better communicated to the recipient.
Discussion
Changing the behavioural patterns of prescribers in particular has been the focus of extensive research, and barriers to change such as lack of awareness, knowledge, motivation, belief and skill, as well as practical, financial and politi cal obstacles have been identified. 7 It is important for practitioners to be as aware as possible of any gaps in their knowl edge about medicines they are prescrib ing or supplying and the DSU newsletter potentially provides a useful resource.
In our small survey, awareness of this monthly newsletter was mixed, with 8% of GPs, 10% of pharmacists and approx imately a quarter of NMPs indicating they infrequently or never get to see the actual newsletter. The CCG prescribing team was seen to have an important role in promulgating DSU messages with between 50% and 82% of professionals responding that they receive notification about DSU from the CCG. For organisa tions such as CCGs, having a medica tion/prescribing communication strategy directed at practices is important for the promotion of highquality prescribing. 8 Though a majority of respondents from each profession (63-81%) acknowl edged that a few of the topics are rel evant and they have an understanding of any necessary action, a third of GPs thought that for some topics relevant to them, it was not clear what action should be taken. This is a potential concern as prescribers need a concise assessment of any safety risk that makes it easy for them to bring about change in clini cal practice at the point of prescribing. Others have argued that pharmaceuti cal companies and licensing authorities should word the information in Dear Doctor letters more precisely and, above all, in a way that allows the information to be put into practice by clinicians. 9 The Drug and Therapeutics Bulletin rec ognises that leaving healthcare profes sionals without a clear indication of the severity, urgency and appropriate course of action increases the risk of a frag mented and incomplete response. 6 In a survey of over 1000 Dutch doc tors and pharmacists, almost onethird reported taking action following a direct healthcare professional communication. 3 This might be considered a disappoint ing figure, but the authors argued that in some other areas, achieving a behav ioural impact by a single act of com munication in onethird of the targeted audience would be seen as a success. A much larger survey (with over 3000 respondents) across nine European countries found that healthcare profes sionals are generally familiar with the safety communication tools (ie direct healthcare professional communications and national competent authority com munications) and these tools are consid ered useful. 10 Of the 32 respondents who gave spe cific examples of where they thought DSU had altered the prescribing or monitoring of drug use, valproate was mentioned the most frequently (10 instances) and domperidone the second most frequently (seven instances). Changes in the pre scribing of domperidone in general prac tice subsequent to the DSU warning 11 have been noted in two reports, though in both these reports it would appear that additional focused action was required within the surgeries to ensure that med ication safety alerts were integrated into practice. 12, 13 A further report noted no significant change on domperidone pre scribing patterns in Ireland. 14 Safety topics identified through DSU may impact on both hospital and primary care prescribers, and the opinion of the specialist may be sought for some indi vidual patients. When primary care seeks advice, this hopefully emphasises to the specialist (and their junior hospital doc tors) that there is a safety issue with the named drug and that both primary and secondary care need to respond to DSU topics together to mitigate risk.
As stated earlier, safety warnings have been shown to have variable effects on medicine usage. 1517 In an observa tional study examining the impact of risk communications on antipsychotic prescribing, the authors concluded that risk communications from regulators do change clinical practice, although the study raised important questions about how such risk communications should best be designed and disseminated. 18 A similar study looking at antipsychotic prescribing in the UK and Italy noted that safety warnings combined with proactive national initiatives in the UK may have contributed to a more sustained reduc tion in prescribing than occurred in Italy. 19 A 2005 study evaluated the quality of a group of direct healthcare profes sional communication letters sent during 2000 and 2001 that were intended to communicate important new drug safety information. 20 This study found a corre lation between the perceived quality of the letter and the extent to which physi cians regarded the new information as important. Letters that were evaluated as clearer, more concise, and better organ ised and formatted, and that focused on the most important aspects of the new safety information were considered more effective in communicating the new infor mation.
Furthermore, a survey of healthcare professionals in nine European countries found that the perceived usefulness of the safety communication, and the trust worthiness of the national competent authority, influenced how often health care professionals took action. 21 The small number of free text com ments in our Cornish survey supports the need for a clear, concise message that is unambiguous in describing the action to be taken. Computerised decision sup port software such as OptimiseRx and ScriptSwitch can be utilised to prompt prescribers about safety updates and any necessary action to be taken at the time of prescribing the target drug.
Limitations of our study include the relatively small sample size, and the reli ance of the survey on selfreporting with the associated potential for social desir ability bias where respondents may have given expected, anticipated answers. Attempts to minimise this bias were made by emphasising that the responses would be processed anonymously. In addition, there were limitations asso ciated with delivering a questionnaire that was brief and consisted of mainly closedended questions, which limited the respondents to the answers provided on the questionnaire, as well as gauging the views of GPs who, in their role of prac tice prescribing lead, could be described as a selfselected group.
Conclusion
This small study has identified deficien cies in how patient safety information is received and effectively translated into practice by a range of healthcare profes sionals. Additional efforts are needed to ensure that such information reaches healthcare professionals in such a way that enables appropriate action to be undertaken. Medicines optimisation teams have a role in signposting to and promoting DSU messages, while decision support software can potentially inter vene at the point of prescribing.
